| Name | Tigecycline |
| Description | Tigecycline (GAR-936) is a broad-spectrum glycylcycline antibiotic derived from tetracycline that binds to the 30S ribosomal subunit, disrupting the binding of aminoacyl-tRNA to the mRNA-ribosome complex. |
| In vitro | Tigecycline inhibited methicillin-resistant Staphylococcus aureus in a rabbit model of osteomyelitis. Tigecycline was shown to be resistant to Legionella pneumophila in guinea pigs with Legionella pneumophila pneumonia. |
| In vivo | Tigecycline, a substrate for the tetracycline-specific efflux pump, exhibits antibacterial activity against a wide range of aerobic and anaerobic bacteria. For enterococci, staphylococci and streptococci (MIC=0.06-0.25 mg / L), Tigecycline was able to produce bacteriostatic effects. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 93 mg/mL (158.8 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (5.63 mM), Sonication is recommended.
H2O : 92 mg/mL (157.09 mM), Sonication is recommended.
|
| Keywords | Tigecycline | Inhibitor | inhibit | GAR936 | GAR 936 | Bacterial | Autophagy | Antibiotic | 30S ribosome |
| Inhibitors Related | Neomycin sulfate | Aceglutamide | Hemin | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Sulfamethoxazole sodium | Terbinafine hydrochloride | Hydroxychloroquine | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Pediatric Drug Library | EMA Approved Drug Library | Drug Repurposing Compound Library | NO PAINS Compound Library | Anti-Bacterial Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
